Franciszkiewicz Katarzyna, Le Floc'h Audrey, Jalil Abdelali, Vigant Frédéric, Robert Thomas, Vergnon Isabelle, Mackiewicz Andrzej, Benihoud Karim, Validire Pierre, Chouaib Salem, Combadière Christophe, Mami-Chouaib Fathia
Institut National de la Santé et de la Recherche Médicale U753, Laboratoire Immunologie des Tumeurs Humaines, Interaction Effecteurs Cytotoxiques-Système Tumoral,"Institut Fédératif de Recherche-54, Villejuif, France.
Cancer Res. 2009 Aug 1;69(15):6249-55. doi: 10.1158/0008-5472.CAN-08-3571. Epub 2009 Jul 28.
We have reported previously that the interaction of alpha(E)(CD103)beta(7) integrin, expressed on a CD8(+) tumor-infiltrating lymphocyte (TIL) clone but not on a peripheral blood lymphocyte (PBL) counterpart, with the epithelial marker E-cadherin on human lung tumor cells plays a crucial role in T-cell receptor-mediated cytotoxicity. We show here that both TIL and PBL clones are able to migrate toward autologous tumor cells and that chemokine receptor CCR5 is involved in this process. Adoptive transfer of the PBL clone in the cognate tumor engrafted in nonobese diabetic/severe combined immunodeficient mice and subsequent coengagement of T-cell receptor and transforming growth factor-beta1 receptor triggers CD103 expression on T-cell surface resulting in strong potentiation of antitumor lytic function. Moreover, interaction of alpha(E)beta(7) integrin with E-cadherin, but not lymphocyte function-associated antigen-1 with intercellular adhesion molecule-1, promotes CCR5 recruitment at the immunologic synapse formed between TIL and tumor cells, leading to inhibition of T-cell sensitivity to CCL5 chemotactic gradient. These results provide evidence for a role of tumor microenvironment, namely MHC class I-restricted antigen presentation and transforming growth factor-beta1 secretion, in regulating the effector phase of tumor-specific CTL response. They also suggest a unique role of CD103 in T-cell retention at the tumor site by a CCR5-dependent mechanism.
我们之前报道过,表达于一个CD8(+)肿瘤浸润淋巴细胞(TIL)克隆而非外周血淋巴细胞(PBL)对应物上的α(E)(CD103)β(7)整合素,与人类肺癌细胞上的上皮标志物E-钙黏蛋白的相互作用在T细胞受体介导的细胞毒性中起关键作用。我们在此表明,TIL和PBL克隆均能够向自体肿瘤细胞迁移,且趋化因子受体CCR5参与此过程。将PBL克隆过继转移至植入同源肿瘤的非肥胖糖尿病/重症联合免疫缺陷小鼠体内,随后T细胞受体和转化生长因子-β1受体的共同作用会触发T细胞表面CD103的表达,从而导致抗肿瘤裂解功能的强烈增强。此外,α(E)β(7)整合素与E-钙黏蛋白的相互作用,而非淋巴细胞功能相关抗原-1与细胞间黏附分子-1的相互作用,会促进CCR5在TIL与肿瘤细胞之间形成的免疫突触处募集,导致T细胞对CCL5趋化梯度的敏感性受到抑制。这些结果为肿瘤微环境(即MHC I类限制性抗原呈递和转化生长因子-β1分泌)在调节肿瘤特异性CTL反应的效应阶段中的作用提供了证据。它们还表明CD103通过依赖CCR5的机制在T细胞滞留于肿瘤部位中发挥独特作用。